Watertown, Massachusetts, United States, July 2024 – C4 Therapeutics, Inc. is excited to announce the appointment of Alexis McManamon as the new Senior Director, Human Resources. Alexis brings a wealth of experience in HR leadership and a proven track record of enhancing organizational effectiveness and employee engagement. In her new role, she will oversee strategic HR initiatives to support C4 Therapeutics’ mission and growth.
Alexis McManamon joins C4 Therapeutics from Orna Therapeutics, where she served as the Director, People Partner. During her tenure from August 2022 to June 2024, she played a pivotal role in driving people strategies and supporting organizational development in Cambridge, Massachusetts.
Prior to her role at Orna Therapeutics, Alexis was the Associate Director Human Resources at Rheos Medicines from October 2021 to July 2022. In this role, she led HR operations and contributed to the company’s strategic planning and employee engagement initiatives.
Alexis also spent over six years at Jounce Therapeutics, Inc., where she held multiple positions, including Senior HR Business Partner & Manager, Learning and Development, Senior Human Resources Business Partner, and Human Resources Business Partner. Her contributions were instrumental in shaping the company’s HR policies and fostering a positive work environment.
Earlier in her career, Alexis worked at Synageva BioPharma Corp. as a Recruiting Coordinator and at Sylvan Learning as a Center Director. She also gained extensive experience in retail management, holding positions such as Store Manager at Vineyard Vines, kate spade new york, and Coach.
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets, and improve patient outcomes.
Read Also : The Power of Silence: How Leaders Can Harness the Art of Not Responding Immediately
